Age-related Macular Degeneration Market Size, Share, Growth Analysis, By Drug Type(Aflibercept, Ranibizumab, and Others), By Disease Type(Wet Age-Related Macular Degeneration (AMD) and Dry Age-Related Macular Degeneration (AMD)), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region - Industry Forecast 2024-2031

Drivers

Rising Aging Population

• Increased elderly population being susceptible to AMD is driving the global age-related macular degeneration market. The longer people live, the more they are exposed to its risk which leads in turn to requests for AMD therapies and treatments so as to manage and stop sight loss.

Advancements in Treatment Options:

• The proliferation of the market due to the novel anti-VEGF medicines and up-and-coming gene therapies are some of the innovations in AMD treatments. With better treatment effectiveness and longer drug intervals, health results for patients improve, which causes an increase in utilization rates thereby enhancing the potential for more expansion in the sector.

Restraints

Lack of Early Diagnosis

• Screening and diagnostics for AMD are not enough in some places until you have a look at how it impacts everything else such as poor outcomes and treatment delays. The lack of information about available diagnostic tools also limits market growth as individuals tend to get late interventions and this reduces the efficiency of existing therapies.

Limited Reimbursement Coverage

• The progression of the market can be affected by the variable policies for reimbursement and coverage of treatments related to AMD. Patients may avoid seeking treatment if their insurance does not cover it, or this may limit the use of newer therapy types altogether. This will ultimately affect Market Growth and Access.